Trial Profile
The treatment of dementia with acetylcholinesterase inhibitors: analysis of plasma concentrations, drug interactions and therapeutic effect as a function of genetic polymorphisms [Die antidementive Therapie mit Acetylcholinesteraseinhibitoren: Untersuchung von Plasmakonzentrationen, Arzneimittelinteraktionen und Therapieeffekt in Abhangigkeit von genetischen Polymorphismen]
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 24 Dec 2021
Price :
$35
*
At a glance
- Drugs Donepezil (Primary) ; Galantamine (Primary) ; Rivastigmine (Primary)
- Indications Alzheimer's disease; Dementia
- Focus Pharmacogenomic; Pharmacokinetics
- 22 Dec 2021 Status changed from recruiting to completed.
- 24 Aug 2011 New trial record